Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil

N Fujiyama, M Miura, S Kato, T Sone, M Isobe… - Drug metabolism and …, 2010 - ASPET
Mycophenolate mofetil (MMF) is the ester prodrug of the immunosuppressant agent
mycophenolic acid (MPA) and is rapidly activated by esterases after oral administration. However, …

Advanced tertiary lymphoid tissues in protocol biopsies are associated with progressive graft dysfunction in kidney transplant recipients

…, S Yamamoto, A Komatsuda, N Fujiyama… - Journal of the …, 2022 - journals.lww.com
Background Tertiary lymphoid tissues (TLTs) are ectopic lymphoid tissues found in chronically
inflamed organs. Although studies have documented TLT formation in transplanted …

Involvement of human blood arylesterases and liver microsomal carboxylesterases in nafamostat hydrolysis

S Yamaori, N Fujiyama, M Kushihara… - Drug metabolism and …, 2006 - Elsevier
Metabolism of nafamostat, a clinically used serine protease inhibitor, was investigated with
human blood and liver enzyme sources. All the enzyme sources examined (whole blood, …

[HTML][HTML] A nationwide survey of hepatitis E virus infection and chronic hepatitis in heart and kidney transplant recipients in Japan

…, Y Oshiro, Y Inagaki, H Harada, N Fujiyama… - …, 2020 - journals.lww.com
Background. Recently, chronic hepatitis E has been reported in solid organ transplant (SOT)
recipients in European countries. Previously, we clarified the prevalence of hepatitis E virus …

Impact of germline HLA genotypes on clinical outcomes in patients with urothelial cancer treated with pembrolizumab

S Takahashi, S Narita, N Fujiyama… - Cancer …, 2022 - Wiley Online Library
Human leukocyte antigen class I (HLA‐I) genotypes are suggested to influence the cancer
response to checkpoint blockade immunotherapy. This study assessed the impact of germline …

Contribution of UGT1A1 genetic polymorphisms related to axitinib pharmacokinetics to safety and efficacy in patients with renal cell carcinoma

R Igarashi, T Inoue, N Fujiyama, N Tsuchiya… - Medical Oncology, 2018 - Springer
Axitinib is a potent second-line molecular-targeted agent for metastatic renal cell carcinoma
(mRCC). Axitinib pharmacokinetics and its relation with genetic polymorphisms were …

Effect of HLA genotype on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle-invasive bladder cancer

M Kobayashi, N Fujiyama, T Tanegashima… - Cancer Immunology …, 2022 - Springer
The intravesical administration of bacillus Calmette–Guérin (BCG) is widely used to control
the intravesical recurrence of non-muscle-invasive bladder cancer (NMIBC). This study …

[HTML][HTML] Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell …

K Numakura, N Fujiyama, M Takahashi, R Igarashi… - Oncotarget, 2018 - ncbi.nlm.nih.gov
In this study, we examined the association between the pharmacokinetics (PK) level of
sunitinib malate (SU) and its metabolite N-desethyl-sunitinib (DSU) in terms of adverse events (…

Association of pharmacokinetics of axitinib with treatment outcome and adverse events in advanced renal cell carcinoma patients.

N Tsuchiya, R Igarashi, N Suzuki-Honma, N Fujiyama… - 2015 - ascopubs.org
506 Background: Therapeutic drug monitoring (TDM) has been recognized as a useful tool
for optimizing the dose of many drugs. The effectiveness of TDM for molecular targeted …

Down-regulation of hepatic transporters for BSP in rats with indomethacin-induced intestinal injury

N Fujiyama, Y Shitara, K Ito, Y Masubuchi… - Biological and …, 2007 - jstage.jst.go.jp
MATERIALS AND METHODS Chemicals IDM was purchased from Wako Pure Chemical
Industries (Osaka, Japan). BSP was purchased from Sigma-Aldrich (St. Louis, MO, USA) …